Exagen (XGN) Stock Forecast, Price Target & Predictions
XGN Stock Forecast
Exagen stock forecast is as follows: an average price target of $6.00 (represents a 91.08% upside from XGN’s last price of $3.14) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
XGN Price Target
The average price target for Exagen (XGN) is $6.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $5.00. This represents a potential 91.08% upside from XGN's last price of $3.14.
XGN Analyst Ratings
According to 2 Wall Street analysts, Exagen's rating consensus is 'Buy'. The analyst rating breakdown for XGN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Exagen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 14, 2024 | Kyle Mikson | Canaccord Genuity | $5.00 | $1.64 | 204.88% | 59.24% |
| Nov 17, 2022 | - | BTIG | $7.00 | $3.40 | 105.88% | 122.93% |
The latest Exagen stock forecast, released on May 14, 2024 by Kyle Mikson from Canaccord Genuity, set a price target of $5.00, which represents a 204.88% increase from the stock price at the time of the forecast ($1.64), and a 59.24% increase from XGN last price ($3.14).
Exagen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.00 |
| Last Closing Price | $3.14 | $3.14 | $3.14 |
| Upside/Downside | -100.00% | -100.00% | 59.24% |
In the current month, the average price target of Exagen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Exagen's last price of $3.14. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 14, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Mar 22, 2023 | BTIG | Buy | Buy | Hold |
Exagen's last stock rating was published by Cantor Fitzgerald on May 14, 2024. The company gave XGN a "Overweight" rating, the same as its previous rate.
Exagen Financial Forecast
Exagen Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $13.77M | $13.42M | $14.14M | $11.23M | $12.84M | $14.73M | - | $10.39M | $12.69M | $12.25M | $12.77M | $10.59M | $12.67M | $10.78M | $8.95M | $9.58M | $10.21M | $10.44M |
| Avg Forecast | $17.20M | $17.19M | $18.91M | $15.71M | $17.11M | $16.20M | $16.10M | $14.79M | $14.17M | $13.57M | $13.13M | $13.09M | $11.56M | $10.33M | $10.93M | $9.41M | $8.66M | $9.04M | $12.03M | $10.00M | $11.71M | $12.13M | $11.48M | $10.45M | $10.69M | $8.72M | $4.67M | $7.73M | $10.43M | $9.02M |
| High Forecast | $17.87M | $17.86M | $19.65M | $16.32M | $17.78M | $16.84M | $16.73M | $15.36M | $14.72M | $13.62M | $13.64M | $13.60M | $11.83M | $10.73M | $11.36M | $9.77M | $9.00M | $9.40M | $12.03M | $10.10M | $11.83M | $12.25M | $11.60M | $10.56M | $10.80M | $8.81M | $4.71M | $7.81M | $10.54M | $9.11M |
| Low Forecast | $16.73M | $16.72M | $18.39M | $15.28M | $16.64M | $15.76M | $15.66M | $14.38M | $13.78M | $13.52M | $12.77M | $12.73M | $11.32M | $10.05M | $10.63M | $9.15M | $8.42M | $8.80M | $12.03M | $9.92M | $11.62M | $12.04M | $11.39M | $10.37M | $10.61M | $8.66M | $4.63M | $7.68M | $10.35M | $8.95M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.19% | 1.30% | 1.29% | 1.19% | 1.48% | 1.63% | - | 1.04% | 1.08% | 1.01% | 1.11% | 1.01% | 1.18% | 1.23% | 1.92% | 1.24% | 0.98% | 1.16% |
Exagen's average Quarter revenue forecast for Mar 24 based on 2 analysts is $13.09M, with a low forecast of $12.73M, and a high forecast of $13.60M. XGN's average Quarter revenue forecast represents a -4.93% decrease compared to the company's last Quarter revenue of $13.77M (Dec 23).
Exagen EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-4.64M | $-5.07M | $-4.92M | $-6.50M | $-8.50M | $-7.48M | - | $-9.39M | $-5.95M | $-6.25M | $-5.53M | $-5.38M | $-2.61M | $-3.52M | $-2.60M | $-4.92M | $-2.50M | $-2.12M |
| Avg Forecast | $-7.98M | $-7.97M | $-8.77M | $-7.29M | $-7.94M | $-7.51M | $-7.47M | $-6.86M | $-6.57M | $-6.29M | $-6.09M | $-6.07M | $-5.36M | $-4.79M | $-5.07M | $-4.36M | $-4.02M | $-7.04M | $-5.58M | $-9.00 | $-5.43M | $-6.40M | $-6.85M | $-5.26M | $-4.96M | $-4.05M | $-3.85M | $-5.43M | $-4.84M | $-2.20M |
| High Forecast | $-7.76M | $-7.75M | $-8.53M | $-7.09M | $-7.72M | $-7.31M | $-7.26M | $-6.67M | $-6.39M | $-6.27M | $-5.92M | $-5.90M | $-5.25M | $-4.66M | $-4.93M | $-4.24M | $-3.91M | $-5.63M | $-5.58M | $-7.00 | $-5.39M | $-5.12M | $-5.48M | $-4.21M | $-4.92M | $-4.02M | $-3.08M | $-4.34M | $-4.80M | $-1.76M |
| Low Forecast | $-8.29M | $-8.28M | $-9.11M | $-7.57M | $-8.25M | $-7.81M | $-7.76M | $-7.12M | $-6.83M | $-6.32M | $-6.33M | $-6.31M | $-5.49M | $-4.98M | $-5.27M | $-4.53M | $-4.17M | $-8.44M | $-5.58M | $-11.00 | $-5.48M | $-7.68M | $-8.22M | $-6.32M | $-5.01M | $-4.09M | $-4.62M | $-6.51M | $-4.89M | $-2.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.87% | 1.06% | 0.97% | 1.49% | 2.12% | 1.06% | - | 1043444.44% | 1.10% | 0.98% | 0.81% | 1.02% | 0.53% | 0.87% | 0.68% | 0.91% | 0.52% | 0.96% |
undefined analysts predict XGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Exagen's previous annual EBITDA (undefined) of $NaN.
Exagen Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-5.57M | $-5.42M | $-5.01M | $-8.31M | $-14.35M | $-2.37M | - | $-10.87M | $-7.05M | $-7.18M | $-6.41M | $-6.21M | $-3.45M | $-4.31M | $-3.36M | $-5.56M | $-3.41M | $-3.14M |
| Avg Forecast | $-2.00M | $-2.00M | $-1.64M | $-3.09M | $-3.14M | $-3.73M | $-3.82M | $-4.59M | $-5.73M | $-5.27M | $-6.18M | $-6.56M | $-7.83M | $-8.54M | $-9.01M | $-10.21M | $-13.94M | $-8.08M | $-10.21M | $-10.00 | $-8.57M | $-7.35M | $-7.95M | $-6.08M | $-7.07M | $-8.43M | $-4.98M | $-6.13M | $-6.54M | $-3.27M |
| High Forecast | $-1.93M | $-1.93M | $-1.58M | $-2.98M | $-3.02M | $-3.59M | $-3.68M | $-4.43M | $-5.52M | $-5.08M | $-5.96M | $-6.33M | $-7.55M | $-8.24M | $-8.69M | $-9.85M | $-13.45M | $-6.46M | $-10.21M | $-8.00 | $-8.49M | $-5.88M | $-6.36M | $-4.86M | $-7.00M | $-8.35M | $-3.98M | $-4.90M | $-6.48M | $-2.62M |
| Low Forecast | $-2.10M | $-2.10M | $-1.72M | $-3.25M | $-3.29M | $-3.92M | $-4.01M | $-4.82M | $-6.02M | $-5.54M | $-6.49M | $-6.89M | $-8.22M | $-8.98M | $-9.47M | $-10.73M | $-14.65M | $-9.70M | $-10.21M | $-12.00 | $-8.68M | $-8.82M | $-9.54M | $-7.29M | $-7.17M | $-8.54M | $-5.97M | $-7.36M | $-6.63M | $-3.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.71% | 0.63% | 0.56% | 0.81% | 1.03% | 0.29% | - | 1086500.00% | 0.82% | 0.98% | 0.81% | 1.02% | 0.49% | 0.51% | 0.68% | 0.91% | 0.52% | 0.96% |
Exagen's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. XGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Exagen SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $12.22M | $11.38M | $11.95M | $11.88M | $12.81M | $14.15M | - | $12.15M | $11.80M | $11.53M | $11.17M | $10.04M | $9.93M | $9.20M | $8.28M | $9.63M | $7.92M | $7.31M |
| Avg Forecast | $15.68M | $15.68M | $17.24M | $14.33M | $15.60M | $14.77M | $14.68M | $13.48M | $12.92M | $12.38M | $11.97M | $11.93M | $10.54M | $9.42M | $9.97M | $8.58M | $7.90M | $8.25M | $10.97M | $11.00 | $10.68M | $11.80M | $10.47M | $9.83M | $9.75M | $7.96M | $4.26M | $7.05M | $9.51M | $7.61M |
| High Forecast | $16.30M | $16.29M | $17.92M | $14.89M | $16.21M | $15.35M | $15.26M | $14.01M | $13.43M | $12.42M | $12.44M | $12.40M | $10.79M | $9.79M | $10.36M | $8.91M | $8.20M | $8.57M | $10.97M | $14.00 | $10.78M | $14.16M | $10.57M | $11.79M | $9.85M | $8.04M | $4.30M | $7.12M | $9.61M | $9.13M |
| Low Forecast | $15.26M | $15.25M | $16.77M | $13.93M | $15.18M | $14.37M | $14.28M | $13.11M | $12.57M | $12.33M | $11.64M | $11.61M | $10.32M | $9.16M | $9.70M | $8.34M | $7.68M | $8.02M | $10.97M | $9.00 | $10.60M | $9.44M | $10.39M | $7.86M | $9.68M | $7.90M | $4.22M | $7.00M | $9.44M | $6.09M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.16% | 1.21% | 1.20% | 1.39% | 1.62% | 1.72% | - | 1104727.27% | 1.11% | 0.98% | 1.07% | 1.02% | 1.02% | 1.16% | 1.94% | 1.37% | 0.83% | 0.96% |
Exagen's average Quarter SG&A projection for Mar 24 is $11.93M, based on 2 Wall Street analysts, with a range of $11.61M to $12.40M. The forecast indicates a -2.32% fall compared to XGN last annual SG&A of $12.22M (Dec 23).
Exagen EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.31 | $-0.00 | $-0.00 | $-0.47 | $-0.84 | $-0.14 | - | $-0.64 | $-0.42 | $-0.42 | $-0.38 | $-0.48 | $-0.27 | $-0.34 | $-0.27 | $-0.44 | $-0.27 | $-11.29 |
| Avg Forecast | $-0.11 | $-0.11 | $-0.09 | $-0.17 | $-0.17 | $-0.20 | $-0.21 | $-0.25 | $-0.32 | $-0.29 | $-0.34 | $-0.36 | $-0.43 | $-0.47 | $-0.50 | $-0.56 | $-0.77 | $-0.77 | $-0.57 | $-0.61 | $-0.48 | $-0.46 | $-0.44 | $-0.47 | $-0.40 | $-0.47 | $-0.76 | $-0.49 | $-0.37 | $-0.58 |
| High Forecast | $-0.11 | $-0.11 | $-0.09 | $-0.16 | $-0.17 | $-0.20 | $-0.20 | $-0.24 | $-0.30 | $-0.28 | $-0.33 | $-0.35 | $-0.42 | $-0.45 | $-0.48 | $-0.54 | $-0.74 | $-0.74 | $-0.57 | $-0.60 | $-0.48 | $-0.46 | $-0.43 | $-0.47 | $-0.39 | $-0.47 | $-0.75 | $-0.49 | $-0.36 | $-0.57 |
| Low Forecast | $-0.12 | $-0.12 | $-0.09 | $-0.18 | $-0.18 | $-0.22 | $-0.22 | $-0.27 | $-0.33 | $-0.30 | $-0.36 | $-0.38 | $-0.45 | $-0.49 | $-0.52 | $-0.59 | $-0.81 | $-0.81 | $-0.57 | $-0.62 | $-0.49 | $-0.47 | $-0.44 | $-0.48 | $-0.40 | $-0.48 | $-0.77 | $-0.50 | $-0.37 | $-0.59 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.72% | 0.00% | 0.00% | 0.84% | 1.10% | 0.18% | - | 1.05% | 0.87% | 0.91% | 0.87% | 1.02% | 0.68% | 0.72% | 0.36% | 0.90% | 0.74% | 19.47% |
According to undefined Wall Street analysts, Exagen's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to XGN previous annual EPS of $NaN (undefined).
Exagen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LMDX | LumiraDx | $0.02 | $1.50 | 7400.00% | Buy |
| DRIO | DarioHealth | $0.84 | $10.75 | 1179.76% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| XGN | Exagen | $3.14 | $6.00 | 91.08% | Buy |
| BDSX | Biodesix | $1.85 | $3.00 | 62.16% | Buy |
| CSTL | Castle Biosciences | $29.32 | $38.00 | 29.60% | Buy |
| SHC | Sotera Health Company | $15.65 | $16.93 | 8.18% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
XGN Forecast FAQ
Is Exagen a good buy?
Yes, according to 2 Wall Street analysts, Exagen (XGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of XGN's total ratings.
What is XGN's price target?
Exagen (XGN) average price target is $6 with a range of $5 to $7, implying a 91.08% from its last price of $3.14. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Exagen stock go up soon?
According to Wall Street analysts' prediction for XGN stock, the company can go up by 91.08% (from the last price of $3.14 to the average price target of $6), up by 122.93% based on the highest stock price target, and up by 59.24% based on the lowest stock price target.
Can Exagen stock reach $5?
XGN's average twelve months analyst stock price target of $6 supports the claim that Exagen can reach $5 in the near future.
What are Exagen's analysts' financial forecasts?
Exagen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.2M (high $66.71M, low $62.45M), average EBITDA is $-29.774M (high $-28.963M, low $-30.937M), average net income is $-15.27M (high $-14.729M, low $-16.045M), average SG&A $58.54M (high $60.83M, low $56.95M), and average EPS is $-0.84 (high $-0.81, low $-0.883). XGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $69.01M (high $71.71M, low $67.13M), average EBITDA is $-32.005M (high $-31.133M, low $-33.255M), average net income is $-8.726M (high $-8.416M, low $-9.169M), average SG&A $62.93M (high $65.39M, low $61.21M), and average EPS is $-0.48 (high $-0.463, low $-0.504).
Did the XGN's actual financial results beat the analysts' financial forecasts?
Based on Exagen's last annual report (Dec 2023), the company's revenue was $52.55M, beating the average analysts forecast of $42.22M by 24.45%. Apple's EBITDA was $-22.837M, beating the average prediction of $-19.583M by 16.62%. The company's net income was $-23.689M, missing the average estimation of $-35.591M by -33.44%. Apple's SG&A was $47.43M, beating the average forecast of $38.5M by 23.18%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.958 by -99.93%. In terms of the last quarterly report (Dec 2023), Exagen's revenue was $13.76M, beating the average analysts' forecast of $11.56M by 19.12%. The company's EBITDA was $-4.64M, missing the average prediction of $-5.359M by -13.42%. Exagen's net income was $-5.573M, missing the average estimation of $-7.825M by -28.78%. The company's SG&A was $12.22M, beating the average forecast of $10.54M by 15.93%. Lastly, the company's EPS was $-0.31, missing the average prediction of $-0.43 by -27.99%